{'fraction_non_alphanumeric': 0.03495145631067961, 'fraction_numerical': 0.0, 'mean_word_length': 5.070588235294117, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Atovaquone (Mepron) suspension approved by FDA. Food and Drug Administration.


 The newly approved use of an Atovaquone (Mepron) suspension for treating mild to moderate Pneumocystis carinii (PCP) in patients unable to tolerate trimethoprim-sulfamethoxazole (TMP-SMX), has shown that it is twice as bioavailable compared with the previously licensed tablet formulation. However, Atovaquone use has produced more deaths than TMP-SMX, a problem that may in part be due to its lack of a broad antibacterial spectrum.
